What is the Future of TIL Therapy in Metastatic Melanoma?

The landscape of metastatic melanoma treatment is shifting toward more personalized, cellular-based approaches. In this interview clip, Muhammad Umair Mushtaq, MD, associate professor of medicine in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, highlighted why the timing of treatment is just as critical as the therapy itself.

While tumor-infiltrating lymphocyte (TIL) therapy has traditionally been viewed as a later-line option, Mushtaq explained the growing excitement surrounding its use in the first-line setting. By intervening before the immune system reaches a state of exhaustion or senescence caused by prior treatments, clinicians hope to harness more robust, fit T-cells for better patient outcomes.

Mushtaq also touched on the next frontier of cellular engineering, including:

• Immune Fitness: The advantages of harvesting TILs earlier in the disease course.
• Genetic Modifications: The potential for PD-1/PD-L1 knockouts to create more resilient cells.
• Combination Strategies: How pairing TILs with standard immunotherapy could amplify efficacy.

Transcript:

There have been trials with TIL therapy in [the] first line setting in the melanoma space, and the results would be exciting from that standpoint, if it responds to immunotherapy and [uses] TILs earlier in the disease course, when the immune fitness is relatively preserved. When you give immunotherapy, you engage patients’ native immune system/immune cells, and that does lead to some sort of immune exhaustion or immune senescence. If you give T-cell therapies earlier in the disease course, those T-cells are relatively fit and may lead to improved outcomes. There is excitement about that.

There are also studies looking at some modifications, but right now, it's just expanded TILs. Could there be modifications such as PD-1, PD-L1, [that would] knockout other engineering to the cells to improve their efficacy? Combining the TILs with immunotherapy may improve outcomes. Some of those studies have been ongoing.